利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.022 秒)

    Enzyme assay of biochemical substances
    5.
    发明授权
    Enzyme assay of biochemical substances 失效
    生化物质酶检测

    公开(公告)号：US5436133A

    公开(公告)日：1995-07-25

    申请号：US865715

    申请日：1992-04-08

    申请人： Tuyosi Fujita ,  Isamu Takagahara

    发明人： Tuyosi Fujita ,  Isamu Takagahara

    IPC分类号： C12Q1/28 ,  C12Q1/32 ,  G01N33/50 ,  G01N33/52

    CPC分类号： C12Q1/32 ,  C12Q1/28 ,  Y10S435/962 ,  Y10S436/825 ,  Y10T436/10

    摘要： This invention relates to an enzyme assay for quantitative analysis of biochemical substances using NAD(P)-NAD(P)H system and utilizing hydrogen peroxide, in which isocitric acid, metal ions and isocitrate dehydrogenase are previously added to a test sample, thereby consuming the endogenous substances that interfere the analysis, and at the same time regenerating NAD(P)H reduced.The isocitrate dehydrogenase is then inactivated by addition of a chelating agent, an enzyme or substrate that generates hydrogen peroxide as reaction product is added simultaneously or thereafter, and the amount of hydrogen peroxide thus formed is measured.Biochemical substances that generate hydrogen peroxide as reaction product can be correctly analyzed by this method with no adverse effect of endogenous substances because these interfering substances have been removed prior to measurement.

    摘要翻译： 本发明涉及使用NAD（P）-NAD（P）H系统并利用过氧化氢定量分析生化物质的酶测定法，其中异丙酸，金属离子和异柠檬酸脱氢酶预先加入到测试样品中，从而消耗 干扰分析的内源性物质，同时还原NAD（P）H。 然后通过加入螯合剂，产生过氧化氢的酶或底物，同时或之后加入异柠檬酸脱氢酶，并测量这样形成的过氧化氢的量。 生成过氧化氢作为反应产物的生化物质可以通过这种方法进行正确分析，无内生物质的不利影响，因为这些干扰物质在测量前已被去除。

    Method of assaying magnesium in human body fluid
    6.
    发明授权
    Method of assaying magnesium in human body fluid 失效
    人体体液中镁的测定方法

    公开(公告)号：US5108905A

    公开(公告)日：1992-04-28

    申请号：US690420

    申请日：1991-04-24

    申请人： Yoshiko Sunahara ,  Shigeru Takata ,  Isamu Takagahara

    发明人： Yoshiko Sunahara ,  Shigeru Takata ,  Isamu Takagahara

    IPC分类号： C12Q1/32 ,  G01N33/84

    CPC分类号： G01N33/84 ,  C12Q1/32 ,  Y10S435/81

    摘要： Disclosed is a method of assaying the content of Mg ions in a human body fluid such as serum, urine or saliva by the use of a reactant solution containing isocitrate dehydrogenase, NADP.sup.+, isocitrate and an excess amount of a chelating agent. Almost all Mg ions as existing in a human body fluid sample to be examined are bonded with the chelating agent, and the remaining Mg ions react with NADP.sup.+ to form NADPH. Increase of the thus formed NADPH is measured to obtain a standard curve of a straight line, and the content of Mg ions in the same is determined on the basis of the standard curve. If such an excess amount of a Mg-chelating agent is not added to the reactant solution, the intended standard could not be in the form of a straight line but is in the form of a tangent curve. Using the tangent curve, the content of Mg ions in the human body fluid sample cannot be assayed accurately.

    Diagnostic method of cirrhosis and hepatic cancer
    7.
    发明授权
    Diagnostic method of cirrhosis and hepatic cancer 失效
    肝硬化和肝癌诊断方法

    公开(公告)号：US4994374A

    公开(公告)日：1991-02-19

    申请号：US362414

    申请日：1989-05-01

    申请人： Atsushi Nishikawa ,  Naoyuki Taniguchi ,  Isamu Takagahara

    发明人： Atsushi Nishikawa ,  Naoyuki Taniguchi ,  Isamu Takagahara

    IPC分类号： G01N33/50 ,  A61K47/48 ,  C12Q1/48 ,  G01N33/573 ,  G01N33/574

    CPC分类号： A61K47/48238 ,  C12Q1/48 ,  G01N33/57438 ,  G01N33/57469

    摘要： This invention relates to a method of diagnosing cancerous diseases, which comprises measuring the amount of UDP-N-acetylglucosamine:glycoprotein N-acetylglucosaminyl-transferase in body fluid and evaluating the increase in its amount for the diagnosis of hepatic diseases.AFP, CEA and .gamma.-glutamyltranspeptidase have hitherto been used as tumor markers for the diagnosis of hepatic cancer. But these conventional tumor markers show a positivity rate of about 60%, making early diagnosis almost impossible.The method of this invention employs UDP-N-acetylglucosamine:glycoprotein N-acetylglucosaminyltransferase as tumor marker, whereby early diagnosis of hepatic cancer can be made almost completely.

    摘要翻译： PCT No.PCT / JP88 / 00898 Sec。 371日期：1989年5月1日 102（e）日期1989年5月1日PCT提交1988年9月6日PCT公布。 出版物WO89 / 02474 本发明涉及一种诊断癌性疾病的方法，其包括测量体液中UDP-N-乙酰葡糖胺：糖蛋白N-乙酰氨基葡糖转移酶的量，并评估其用于诊断的量的增加 肝病。 AFP，CEA和γ-谷氨酰转肽酶迄今已被用作肝癌诊断的肿瘤标志物。 但这些常规肿瘤标志物的阳性率约为60％，使得早期诊断几乎不可能。 本发明的方法采用UDP-N-乙酰氨基葡萄糖：糖蛋白N-乙酰葡糖胺基转移酶作为肿瘤标志物，从而能够几乎完全地进行肝癌的早期诊断。